Hester Biosciences Ltd

Ashish Desai, Group Finance Controller at Hester Biosciences, is a Chartered Accountant with over 25 years of experience in accounting, finance, auditing, costing, and taxation. He has driven key initiatives in financial restructuring, treasury management, trade finance, and cost optimization, while strengthening systems and internal controls. Before joining Hester, he served as CFO at Blue Ray Aviation and previously held senior finance roles at Shreeyam Power & Steel Industries and other organizations. Hester Biosciences is one of the leading animal health care companies & the second-largest poultry vaccine manufacturer in India. The company's consolidated net profit surged 76.2% to Rs 14.45 crore on a 15.2% drop in revenue from operations to Rs 70.97 crore in Q2 FY26 over Q2 FY25. Shares of Hester Biosciences rose 0.59% to Rs 1,672 on the BSE.Powered by Capital Market - Live

Hester Biosciences announced the appointment of Ashish Desai as Chief Financial Officer and Key Managerial Personnel of the Company (categorised as Senior Management Personnel), presently serving as Group Finance Controller will assume the role of Chief Financial Officer of the Company with effect from 20 November 2025.Powered by Capital Market - Live

Net profit of Hester Biosciences rose 76.22% to Rs 14.45 crore in the quarter ended September 2025 as against Rs 8.20 crore during the previous quarter ended September 2024. Sales declined 15.20% to Rs 70.97 crore in the quarter ended September 2025 as against Rs 83.69 crore during the previous quarter ended September 2024. ParticularsQuarter EndedSep. 2025Sep. 2024% Var. Sales70.9783.69 -15 OPM %16.5122.89 - PBDT21.3916.07 33 PBT17.0411.87 44 NP14.458.20 76 Powered by Capital Market - Live

Hester Biosciences will hold a meeting of the Board of Directors of the Company on 12 November 2025.Powered by Capital Market - Live

Net profit of Hester Biosciences rose 159.31% to Rs 16.44 crore in the quarter ended June 2025 as against Rs 6.34 crore during the previous quarter ended June 2024. Sales rose 2.24% to Rs 84.11 crore in the quarter ended June 2025 as against Rs 82.27 crore during the previous quarter ended June 2024. ParticularsQuarter EndedJun. 2025Jun. 2024% Var. Sales84.1182.27 2 OPM %27.1221.45 - PBDT24.3714.73 65 PBT20.1910.59 91 NP16.446.34 159 Powered by Capital Market - Live

Hester Biosciences will hold a meeting of the Board of Directors of the Company on 1 August 2025.Powered by Capital Market - Live

Hester Biosciences has fixed 06 August 2025 as record date to determine the members entitled to receive the proposed final dividend of Rs 7 per equity share (i.e. 70% of the face value of Rs 10 each). Powered by Capital Market - Live

Hester Biosciences announced that the 38th Annual General Meeting(AGM) of the company will be held on 13 August 2025.Powered by Capital Market - Live

The Animal Division, which includes both Ruminants and Pet health products, reported an 8% growth in revenue to Rs 30.53 crore in Q4 FY25. The Poultry Healthcare division's revenue grew by 3% YoY to Rs 46.08 crore during the period under review. While EBITDA expanded by 8% YoY to Rs 14.76 crore, EBITDA margin remained constant at 19%. On a consolidated basis, the company has recorded 76% drop in net profit to Rs 1.54 crore even as a revenues increased by 3% to Rs 81.92 crore in Q4 FY25 over Q4 FY24. For FY25, Hester Bio has registered a net profit of Rs 28.82 crore (up 36% YoY) and revenue from operations of Rs 304.54 crore (up 2% YoY). In its outlook, the company said that it remains focused on deepening its presence across all core segments while maintaining strong operational discipline. The company is on track to launch the Avian Influenza vaccine and expand its portfolio of feed supplements and disinfectants in the Poultry Healthcare Division, creating new domestic and export opportunities. In the Animal Division, efforts will be on broadening the nutritional and therapeutic product range to meet evolving market needs and strengthen market share. Continued investments in product development, supply chain efficiency, and customer engagement will drive sustainable growth. Hester is also prioritising international expansion, with a strong focus on scaling its Africa operations and strengthening its presence in existing and new geographies, aligned with its long-term vision of global leadership in animal healthcare,' the company stated. Hester Biosciences Limited is one of the India's leading animal health company, manufacturing vaccines and health products. It is the second largest poultry vaccine manufacturer, with approximately 35% market share in India. The scrip slipped 3.20% to currently trade at Rs 1643.50 on the BSE. Powered by Capital Market - Live

Net profit of Hester Biosciences declined 73.94% to Rs 1.29 crore in the quarter ended March 2025 as against Rs 4.95 crore during the previous quarter ended March 2024. Sales rose 3.37% to Rs 81.93 crore in the quarter ended March 2025 as against Rs 79.26 crore during the previous quarter ended March 2024. For the full year,net profit rose 45.53% to Rs 27.49 crore in the year ended March 2025 as against Rs 18.89 crore during the previous year ended March 2024. Sales rose 2.15% to Rs 311.10 crore in the year ended March 2025 as against Rs 304.55 crore during the previous year ended March 2024. ParticularsQuarter EndedYear EndedMar. 2025Mar. 2024% Var.Mar. 2025Mar. 2024% Var. Sales81.9379.26 3 311.10304.55 2 OPM %23.4120.09 -19.6317.62 - PBDT7.9213.61 -42 56.3749.13 15 PBT3.759.87 -62 39.5731.95 24 NP1.294.95 -74 27.4918.89 46 Powered by Capital Market - Live